Pdt Partners, LLC United Therapeutics Corp Transaction History

Pdt Partners, LLC

$1.01 Billion
Q1 2024

A detailed history of Pdt Partners, LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Pdt Partners, LLC holds 5,840 shares of UTHR stock, worth $1.86 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

5,840

Previous 9,447 38.18%

Holding current value

$1.86 Million

Previous $2.08 Million 35.44%

% of portfolio

0.13%

Previous 0.24%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$210.76 - $249.51 $760,211 - $899,982	-3,607 Reduced 38.18%	5,840 $1.34 Million
Q4 2023 Feb 14, 2024	SELL	$214.88 - $256.94 $1.76 Million - $2.1 Million	-8,175 Reduced 46.39%	9,447 $2.08 Million
Q3 2023 Nov 14, 2023	BUY	$211.82 - $248.24 $1,059 - $1,241	5 Added 0.03%	17,622 $3.98 Million
Q2 2023 Aug 14, 2023	BUY	$205.19 - $232.99 $1.14 Million - $1.29 Million	5,548 Added 45.97%	17,617 $3.89 Million
Q1 2023 May 15, 2023	BUY	$212.99 - $276.17 $2 Million - $2.59 Million	9,369 Added 347.0%	12,069 $2.7 Million

Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $556,065 - $757,161	2,700 New	2,700 $750,000
Q2 2022 Aug 15, 2022	SELL	$174.81 - $241.14 $1.06 Million - $1.46 Million	-6,065 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$166.16 - $213.96 $1.01 Million - $1.3 Million	6,065 New	6,065 $1.09 Million
Q1 2020 May 15, 2020	SELL	$79.39 - $115.35 $238,805 - $346,972	-3,008 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$78.31 - $95.34 $235,556 - $286,782	3,008 New	3,008 $265,000

Others Institutions Holding UTHR

# of Institutions

561

Shares Held

43.1M

Call Options Held

501K

Put Options Held

529K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $14.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account